Microvascular Therapeutics

Microvascular Therapeutics is a clinical stage biotechnology which pioneers in ultrasound contrast agents and theranostics. Microvascular Therapeutics (MVT) is developing a new improved ultrasound contrast agent MVT-100 via the 505(b)(2) pathway. The founders of MVT developed Definity, the worlds #1 selling ultrasound contrast agent. Definity requires refrigerated temperature storage and has side effect of back pain. MVT-100 is a room temperature storage product and designed to eliminate the back pain. MVT has multiple theranostic products in its pipeline with multi-billion dollar market potential, the first one of which is expected to be regulated via the device pathway

Ultrasound contrast agent,theranostics,imaging,and vascular thrombosis

Microvascular therapeutics operates in the Biotechnology research industry.

Microvascular therapeutics's revenue is 1m - 10m

Microvascular therapeutics has 11 - 50 employees.